Newswise — The Cancer Vaccine Collaborative, a joint program of the Cancer Research Institute, Inc. (CRI) and the Ludwig Institute for Cancer Research Ltd (LICR), has been named one of eight finalists for The Collaboration Prize, a national cash award of $250,000 presented to an outstanding model of nonprofit collaboration.
The Lodestar Foundation, in association with the Arizona-Indiana-Michigan (AIM) Alliance, created The Collaboration Prize in an effort to demonstrate how nonprofit resources can be used more effectively to create greater impact. The Cancer Vaccine Collaborative was selected from a competitive pool of over 644 U.S.-based nominations.
The Cancer Vaccine Collaborative (the Collaborative) is the world's only international network of cancer vaccine clinical trials sites and immune monitoring laboratories. It was established in 2001 by CRI and LICR to address their shared goal of accelerating the development of therapeutic cancer vaccines.
"The formation of the Collaborative was motivated by our realization that our two organizations share common objectives," says CRI executive director Jill O'Donnell-Tormey, Ph.D. "These goals—understanding the immunological response to cancer, harnessing that knowledge for patient benefit, and accelerating the translation of basic research into new cancer therapies—could best be achieved by combining our resources and requiring that our scientists collaborate rather than compete."
According to Mr. Edward A. McDermott Jr., LICR president, The Lodestar Foundation is to be congratulated for highlighting such collaborations. "This couldn't be a more timely moment to celebrate the successful sharing of resources and responsibilities by non-profits. We can do so much more, in any charity sector, by combining our strengths rather than competing."
The Collaboration Prize winner will be announced on March 5, 2009 at a seminar in Scottsdale, Arizona on nonprofit effectiveness hosted by Lodestar and the Association of Small Foundations. The winner " chosen by a Final Selection Panel of leaders from the nonprofit and business worlds " will provide the most successful model of collaboration meeting the prize's criteria (as described on the award's Web site, www.thecollaborationprize.org). All eight finalists will be invited to attend the seminar and to participate in panel discussions to share their experiences.
The announcement of the winner will come at a time when many nonprofits are desperately seeking ways to remain viable in an increasingly harsh fundraising environment.
"The economic crisis has decreased charitable giving and that has dramatically increased interest in collaborations and mergers among nonprofits, particularly with respect to eliminating duplication and sharing resources," says Lodestar board chairman, Jerry Hirsch. "Though such strategies can be an imperative during this economic crisis, collaborations and mergers are best practices that should be considered even in the best of economic times."
The CRI/LICR Cancer Vaccine Collaborative includes eminent clinical investigators from leading research and medical clinical trial sites and first-class immune monitoring laboratories, which are supported by a comprehensive independent trials management infrastructure that provides regulatory, safety, and compliance expertise and oversight, trial management, shared data collection software, intellectual property management, and funding.
Collaborative researchers are able to test a wide variety of new reagents and multi-component constructs. By designing complementary trials to be run in parallel at multiple sites, and by standardizing the types of immunological measurements taken, the Collaborative helps to extract the immunological knowledge necessary to eventually optimize a therapeutic vaccine construct, at a significantly accelerated pace compared to efforts carries out solely by competing industry interests.
Since the program's inception in 2001, the Collaborative has completed or is currently conducting more than 35 single-variable, Phase I cancer vaccine trials, as well as a randomized, double-blind, multicenter Phase II cancer vaccine trial, which have produced some of the most comprehensive knowledge on the human immune response to the cancer-specific antigen NY-ESO-1, found in a variety of cancers.
For more information on The Collaboration Prize or for more details on the finalists, please visit www.thecollaborationprize.org.
The other seven Collaboration Prize Finalists are:(in alphabetical order)
1. Chattanooga Museums Collaboration, Chattanooga, Tennessee, Administrative collaboration among The Creative Discovery Museum, The Hunter Museum of American Art and the Tennessee Aquarium
2. Crittenton Women's Union, Boston, Massachusetts, Merger of two organizations serving low-income women
3. Museum of Nature and Science, Dallas, Texas, Merger among the Dallas Children's Museum, The Science Place and Dallas Museum of Natural History
4. New York LawHelp Consortium, New York, New York, Collaboration among legal services organizations providing on-line resources
5.Ready, Set, Parent, Buffalo and Lackawanna, New York, Collaboration between organizations supporting at-risk new parents
6. ShoreBank Enterprise Cascadia, Ilwaco, Washington, Merger of two community development financial institutions
7. YMCA/JCC Integration, Sylvania, Ohio (Greater Toledo), Merger of Jewish Community Center and Young Men's Christian Association in Greater Toledo
About the Cancer Research Institute
Since its inception in 1953, the Cancer Research Institute (CRI) has had a singular mission—to support and coordinate laboratory and clinical research that will yield an understanding of the immune system and its response to cancer, with the ultimate goal of developing immunological methods for the treatment, control, and prevention of the disease. To accomplish these goals, CRI supports scientists at all stages of their careers and funds every step of the research process, from basic laboratory studies to clinical trials testing novel immunotherapies. Guided by a Scientific Advisory Council, which includes five Nobel Prize winners and 30 members of the National Academy of Sciences, CRI awards fellowships and grants to scientists around the world. The Institute seeks to advance preclinical and clinical research by serving as the integrating force and facilitator of international collaborations among leading experts within academia and industry. CRI has thus become a catalyst for accelerating the development of cancer vaccines and antibody therapies that are providing new hope to cancer patients.
The Cancer Research Institute has one of the lowest overhead expense ratios among non-profit organizations, with the majority of its resources going directly to the support of its science, medical, and research programs. The Institute has earned a 4-star designation from Charity Navigator, is rated "grade A" by the American Institute of Philanthropy, is a GiveSpot.com Top 100 charity, and bears the seal of excellence from the Better Business Bureau Wise Giving Alliance.The Institute is a 501(c)(3) public charity that raises its funds annually through the generosity of individuals, corporations, and foundations.
For more information, visit http://www.cancerresearch.org.
About the Ludwig Institute for Cancer Research Ltd
The Ludwig Institute for Cancer Research (LICR) is a global not-for-profit institute dedicated to understanding and controlling cancer. With operations at 73 sites in 17 countries, the LICR network quite literally spans the world. LICR has developed an impressive portfolio of reagents, knowledge, expertise, and intellectual property, and has also assembled the personnel, facilities, and practices necessary to patent, clinically evaluate, license, and thus translate, the most promising aspects of its own laboratory research into cancer therapies. Visit www.licr.org for more information.
RSS